• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

Bydureon teleconf. -someone shut this guy up













Intarcia owns exenatide ~~~ your days are over ~~~~ask Dr John Yee~~

Intarcia’s lead product candidate, ITCA 650 (continuous subcutaneous delivery of exenatide), is currently in Phase 3 development for the treatment of type 2 diabetes. Three Phase 3 studies have been successfully completed, and one is ongoing. Intarcia expects to file for regulatory approval of ITCA 650 in the U.S. in 2016.
 




Intarcia owns exenatide ~~~ your days are over ~~~~ask Dr John Yee~~

Intarcia’s lead product candidate, ITCA 650 (continuous subcutaneous delivery of exenatide), is currently in Phase 3 development for the treatment of type 2 diabetes. Three Phase 3 studies have been successfully completed, and one is ongoing. Intarcia expects to file for regulatory approval of ITCA 650 in the U.S. in 2016.


AZ will buy Intarcia.